(Reuters) - Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor ...

J&J has signed its latest Stelara patent settlement with Fresenius Kabi and Formycon, granting the biosimilar partners a U.S. license date for their drug beginning "no later than April 15, 2025," ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. The ...

WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J ...

As an aside, see 3 Risks That Can Make UnitedHealth Stock Unattractive. Additionally, see: MSFT Stock A Winner In 2026? JNJ ...

Johnson & Johnson recently launched Stelara for the treatment of adult patients with moderate to severe plaque psoriasis. Although Stelara is entering a crowded treatment room for psoriasis, this ...

Dong-A-ST's Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, has won the Food and Drug Administration’s approval. “This FDA approval indicates ...

Johnson & Johnson’s (NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling ...

Johnson & Johnson’s JNJ subsidiary, Janssen Therapeutics, announced that the European Commission (EC) has approved its prescription drug Stelara for the treatment of moderate-to-severely active ...

Johnson & Johnson said on Monday that the Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease. The drug is approved in the ...